Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease

LG Thin-Clients Feature Built-in RFID Capabilities Optimized for Use in Healthcare Facilities

Supporting its mission to help healthcare providers streamline operations and deliver exceptional patient care, LG Business Solutions USA introduced a new LG thin client...

Experien Group Acquired by Veranex

Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets.

Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease.  Daniel G. Clair, MD, vascular surgeon and Chairman of the Department of Surgery at Palmetto Health-USC Medical Group in Columbia, South Carolina presented preliminary results from the company’s clinical development program at the recent Eastern Vascular Society Meeting in Pittsburg, Pennsylvania.

The presentation included outcomes of two cohorts – a non-randomized Phase 2 (n=30; 2 international sites, 2 surgeons) and the open label subset (OL; n=26; 20 U.S. sites, 26 surgeons) of the ACCESS study, an ongoing, randomized, controlled, multicenter US Phase 3 trial.  For the composite study group of 56 patients:

  • 78% and 73% of AVF were suitable for dialysis at 6 and 12 months respectively
  • Median time to first dialysis was 49 days
  • 12-month secondary patency was 73%
  • No product related serious adverse events were reported

These outcomes provide a strong efficacy signal.  Enrollment in the ACCESS study was completed in August 2019 and included 243 patients.  The 6-month primary endpoint (Fistula Suitability for Dialysis at 6 Months) results are expected to be announced in the second quarter of 2020.

Dr. Clair commented “these preliminary results are very encouraging and suggest that intraoperative perivascular sirolimus may improve AV fistula outcomes in dialysis patients.  We look forward to seeing the primary endpoint results from the randomized cohort.”  Maria DeVita, MD, Chief of Nephrology at Lenox Hill Hospital in New York and medical monitor for the study added “Vascular access failures in hemodialysis patients is an important unmet medical need.  I commend Vascular Therapies for developing this therapy and would like to thank the patients, nephrologists, surgeons and clinical coordinators for their participation in these important studies.”




Graham Belgrave Named to the 2021 PharmaVOICE 100 List of Distinguished Leaders

At Advanced Clinical, and from previous organizations, Belgrave serves as a mentor to several colleagues, where he challenges them to think outside of the box and take risks.

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.